申请人:Obika Satoshi
公开号:US20120208991A1
公开(公告)日:2012-08-16
It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2′,4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity
本发明的目的是提供一种新型分子用于反义疗法,该分子在体内不易受核酸酶降解,并且对目标mRNA具有高结合亲和力和特异性,能够有效调节特定基因的表达。本发明的新型人工核苷酸在2′,4′-BNA/LNA的桥接结构中引入了酰胺键。含有2′,4′-桥接人工核苷酸的寡核苷酸与已知的2′,4′-BNA/LNA具有相当的单链RNA结合亲和力,并且比LNA具有更高的核酸酶抗性。特别地,由于其比S-oligo对单链RNA的结合亲和力更强,预计将被应用于核酸药物。